An open label trial of cannabidivarin in patients with Rett syndrome
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Rett syndrome
- Focus Therapeutic Use
- 04 Dec 2017 According to a GW Pharmaceuticals media release, this trial is anticipated to start in 2018.
- 17 May 2017 New trial record
- 09 May 2017 According to a GW Pharmaceuticals media release, this trial is expected to initiate in the fourth quarter of 2017.